Helixgate

Helixgate

Uncategorized

Generic of Novo’s GLP-1 arrives in Canada, a ‘test case for the world’

Published

on

Analysts will be watching as a generic version of semaglutide—marketed by Novo Nordisk as Wegovy for weight loss—launches in Canada as a test case for future price erosion in the U.S.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

What is your AI drug repurposing strategy missing?

Fragmented data limits even the most advanced oncology AI. Curated knowledge changes that.

Read More

Published

on

Fragmented data limits even the most advanced oncology AI. Curated knowledge changes that.

Read More

Continue Reading

Uncategorized

Opinion: Are blue zones real? Answering that question is harder than ever

When French geneticist Jean-Francois Deleuze first launched the AGENOMICS study in 2022, he hoped to identify genetic patterns among 1,200 French citizens who’d lived more than 100 years and to compare those to centenarians hailing from one of the world-famous “blue zones.”

Then he started having doubts.

Read the rest…

Read More

Published

on

When French geneticist Jean-Francois Deleuze first launched the AGENOMICS study in 2022, he hoped to identify genetic patterns among 1,200 French citizens who’d lived more than 100 years and to compare those to centenarians hailing from one of the world-famous “blue zones.”

Then he started having doubts.

Read the rest…

Read More

Continue Reading

Uncategorized

FDA Action Alert: Argenx, AstraZeneca/Daiichi Sankyo, Biogen/Eisai and Cingulate

Published

on

The FDA is looking at a slew of label expansions this month, including one that could open up home-based treatments for Alzheimer’s disease.

Continue Reading
Advertisement

Trending